AbCellera Biologics Inc. ABCL
Set alert
11.12 USD -1.15 -9.37%
At close
11.28 +0.16 +1.44%
Pre-market · Nov 3, 4:55 AM ET
11.05 Day range 12.29
2.75 52-week range 15.02
- YTD
- +225.15%
- 1 year
- +107.08%
- Open
- 12.33
- Prev close
- 12.27
- Mkt cap
- 3.60B
- Vol
- 3.04M
- Avg vol
- 6.40M
- EPS
- -0.54
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 11.05
- High
- 12.29
- Forward P/E
- -14.58
- Beta
- 1.59
- Short ratio
- 5.65
- Inst. own
- 40.76%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 12.29
- 200-d avg
- 6.85
- 1y target
- 17.17
MAX chart
Events in this range
- Aug 7, 2025Earnings: -0.12; estimate -0.17; surprise 29.41%
- Nov 6, 2025Earnings: -0.19; estimate -0.17; surprise -11.76%
- Feb 24, 2026Earnings: -0.03; estimate -0.18; surprise 83.33%
- May 11, 2026Earnings: -0.14; estimate -0.22; surprise 36.36%
- Jul 7, 2026Rating: Benchmark · Hold → Buy
- Aug 5, 2026Earnings: -0.18; estimate -0.164; surprise -9.76%
- Aug 6, 2026Rating: Cantor Fitzgerald · Overweight → Overweight
- Aug 6, 2026Rating: Stifel · Buy → Buy
- Aug 11, 2026Rating: Truist Securities · Buy → Buy
- Sep 29, 2026Rating: JP Morgan · — → Overweight
- Oct 12, 2026Rating: UBS · — → Buy
Signals (80)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 2026 | 1 day ago |
| MACD: Sell Signal | Nov 2, 2026 | 1 day ago |
| SMA: Bullish | Oct 26, 2026 | 1 week ago |
| SMA: Bearish | Oct 12, 2026 | 3 weeks ago |
| RSI: Overbought | Sep 14, 2026 | 1 month ago |
| RSI: Overbought | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| RSI: Overbought | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 13, 2026 | 6 months ago |
| SMA: Bullish | Mar 30, 2026 | 7 months ago |
| SMA: Bearish | Jan 26, 2026 | 9 months ago |
| SMA: Bearish | Jan 12, 2026 | 9 months ago |
| SMA: Bullish | Jan 5, 2026 | 10 months ago |
| SMA: Bullish | Jan 5, 2026 | 10 months ago |
| SMA: Bearish | Nov 3, 2025 | 1 year ago |
| MACD: Sell Signal | Nov 3, 2025 | 1 year ago |
| RSI: Overbought | Sep 29, 2025 | 1 year ago |
| SMA: Bullish | Sep 8, 2025 | 1 year ago |
Newest 20 of 80.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 17.17 +54.4% upside
Now 11.12
- Target (low)
- 9.00
- Target (mean)
- 17.17
- Target (high)
- 30.00
Ratings (0m) 13 12 buy · 1 hold · 0 sell
- Strong buy2
- Buy10
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 13
- 1 month ago 11
- 2 months ago 9
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.17762 | -0.20 – -0.16 | -0.19 | +6.5% | 6.25M | -30.2% | 6 |
| Next quarter | -0.17215 | -0.20 – -0.1429 | -0.03 | -473.8% | 7.05M | -84.3% | 6 |
| Current year | -0.67409 | -0.73 – -0.63 | -0.49 | -37.6% | 26.37M | -64.9% | 8 |
| Next year | -0.76251 | -0.96 – -0.56 | -0.67409 | -13.1% | 28.24M | +7.1% | 7 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | UBS | Initiated | — | Buy |
| Sep 29, 2026 | JP Morgan | Initiated | — | Overweight |
| Aug 11, 2026 | Truist Securities | Maintained | Buy | Buy |
| Aug 6, 2026 | Stifel | Maintained | Buy | Buy |
| Aug 6, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Jul 7, 2026 | Benchmark | Upgrade | Hold | Buy |
| May 5, 2026 | Cantor Fitzgerald | Initiated | — | Overweight |
| Apr 10, 2026 | Jones Trading | Initiated | — | Buy |
| Nov 7, 2025 | Leerink Partners | Downgrade | Outperform | Market Perform |
| Aug 8, 2025 | Stifel | Maintained | Buy | Buy |
| Jul 14, 2025 | Keybanc | Maintained | Overweight | Overweight |
| May 16, 2025 | Truist Securities | Maintained | Buy | Buy |
| May 9, 2025 | Stifel | Maintained | Buy | Buy |
| Apr 16, 2025 | Keybanc | Maintained | Overweight | Overweight |
| Mar 3, 2025 | Benchmark | Reiterated | Hold | Hold |
| Feb 28, 2025 | Stifel | Maintained | Buy | Buy |
| Jan 8, 2025 | Keybanc | Maintained | Overweight | Overweight |
| Nov 5, 2024 | Benchmark | Reiterated | — | Hold |
| Nov 5, 2024 | Stifel | Reiterated | Buy | Buy |
| Aug 20, 2024 | Benchmark | Downgrade | Buy | Hold |
| Jul 11, 2024 | Keybanc | Maintained | Overweight | Overweight |
| May 8, 2024 | Keybanc | Maintained | Overweight | Overweight |
| Feb 22, 2024 | Benchmark | Upgrade | Hold | Buy |
| Feb 21, 2024 | Stifel | Maintained | Buy | Buy |
| Dec 5, 2023 | Keybanc | Initiated | — | Overweight |
| Aug 31, 2023 | Benchmark | Maintained | Buy | Buy |
| Aug 4, 2023 | Goldman Sachs | Maintained | Buy | Buy |
| May 5, 2023 | Credit Suisse | Maintained | — | Outperform |
| Feb 28, 2023 | Cowen & Co. | Initiated | — | Outperform |
| Feb 22, 2023 | BMO Capital | Maintained | — | Outperform |